Pediatr. praxi. 2022;23(4):256-261 | DOI: 10.36290/ped.2023.002

Possibilities of pain treatment in children with selected analgesics

MUDr. Petra Matalová, Ph.D.1, MUC. Benedikt Krížek2
1 Ústav farmakologie LF UP a FN Olomouc
2 Lékařská fakulta Univerzity Palackého v Olomouci

Pain is distressing sensory, emotional and mental experience accompanied by psychological or autonomic symptoms and change of behavior. It is therefore necessary to effectively treat pain using nonpharmacological and pharmacological methods. Pediatric pharmacotherapy has many peculiarities, in the following article we summarize pharmacological treatment options in children, currently used nonopioid and opioid analgesics, their characteristics and the dosage of selected orally used analgesics.

Keywords: pain, analgesic drugs, treatment of pain.

Accepted: August 17, 2022; Published: September 28, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Matalová P, Krížek B. Possibilities of pain treatment in children with selected analgesics. Pediatr. praxi. 2022;23(4):256-261. doi: 10.36290/ped.2023.002.
Download citation

References

  1. Raja SN, Carr DB, Cohen M, et al. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. Pain. 2020;161(9):1976-1982. doi: 10.1097/j.pain.0000000000001939. PMID: 32694387; PMCID: PMC7680716. Go to original source... Go to PubMed...
  2. Hauer J, Jones BL. Evaluation and management of pain in children. In: UpToDate [internet]. [cit. 9-8-2022]. Available from: https://www.uptodate.com/contents/evaluation-and-management-of-pain-in-children.
  3. Harris J, Ramelet AS, van Dijk M, et al. Clinical recommendations for pain, sedation, withdrawal and delirium assessment in critically ill infants and children: an ESPNIC position statement for healthcare professionals. Intensive Care Med. 2016;42(6):972-986. doi: 10.1007/s00134-016-4344-1. Epub 2016 Apr 15. PMID: 27084344; PMCID: PMC4846705. Go to original source... Go to PubMed...
  4. Fitzcharles MA, Cohen SP, Clauw DJ, et al. Nociplastic pain: towards an understanding of prevalent pain conditions. Lancet. 2021;397(10289):2098-2110. doi: 10.1016/S0140-6736(21)00392-5. PMID: 34062144. Go to original source... Go to PubMed...
  5. Matalová P, Navrátilová D, Poruba M. Stručný přehled farmakologických možností léčby bolesti u dětí. Prakt. Lékáren. 2018;14(2):52-54. doi: 10.36290/lek.2018.010 Go to original source...
  6. Birnie KA, Noel M, Chambers CT, et al. Psychological interventions for needle-related procedural pain and distress in children and adolescents. Cochrane Database Syst Rev. 2018 Oct 4;10(10):CD005179. doi: 10.1002/14651858.CD005179.pub4. PMID: 30284240; PMCID: PMC6517234. Go to original source... Go to PubMed...
  7. Kalousová J, Rousková B, Pachmannová D, et al. Bolest u dětí: hodnocení a některé způsoby léčby. Pediatr. Praxi. 2008;9(1):7-11.
  8. Kozák J, Lejčko J, Vrba I. Opioidy. Praha: Mladá fronta; 2018.
  9. Anand KJ. Prevention and treatment of neonatal pain. In: UpToDate [internet]. [cit. 9-8-2022]. Available from: https://www.uptodate.com/contents/prevention-and-treatment-of-neonatal-pain.
  10. Chadwick C, Annandale D, Lazner M, et al. Management of Acute Pain in Children. Pediatric Clinical Practice Guideline. July 2021. In: NHS University Hospitals Sussex [internet]. [cit. 9-8-2022]. Available from: https://www.bsuh.nhs.uk/library/wp-content/uploads/sites/8/2021/07/Paediatric-prescribing-guideline-Acute-Pain-Management-2021.pdf.
  11. de Leeuw TG, Dirckx M, Gonzalez Candel A, et al. The use of dipyrone (metamizol) as an analgesic in children: What is the evidence? A review. Paediatr Anaesth. 2017;27(12):1193-1201. doi: 10.1111/pan.13257. Epub 2017 Oct 12. Erratum in: Paediatr Anaesth. 2018;28(3):309. PMID: 29024184. Go to original source... Go to PubMed...
  12. Ziesenitz VC, Rodieux F, Atkinson A, et al. Dose evaluation of intravenous metamizole (dipyrone) in infants and children: a prospective population pharmacokinetic study. Eur J Clin Pharmacol. 2019;75:1491-1502. Go to original source... Go to PubMed...
  13. Yaffe SJ, Aranda JV, et al. Neonatal and Pediatric Pharmacology. Philadelphia: Lippincott Williams & Wilkins; 2011.
  14. Kanabar DJ. A clinical and safety review of paracetamol and ibuprofen in children. Inflammopharmacology. 2017;25(1):1-9. doi: 10.1007/s10787-016-0302-3. Epub 2017 Jan 6. PMID: 28063133; PMCID: PMC5306275. Go to original source... Go to PubMed...
  15. Jehlička P, Lád V, Sedláček D. Kawasakiho syndrom. Pediatr. Praxi. 2008;9(1):12-14.
  16. David J, Šibíková M, Jonáš J. Závažná komplikace COVID-19 u dětí: syndrom multisystémové zánětlivé odpovědi. Pediatr. praxi. 2021;22(1):8-11. Go to original source...
  17. Diclofenac. In: NHS Medicines A to Z. [internet]. [cit. 9-8-2022]. Available from: https://www.nhs.uk/medicines/diclofenac/.
  18. Medicines Agency's Pharmacovigilance Risk Assessment Committee [PRAC]. Codeine not to be Used in Children Below 12 Years for Cough and Cold. European 2015. In: EMA [internet]. [cit. 9-8-2022]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Codeine_containing_medicinal_products_for_the_treatment_of_cough_and_cold_in_paediatric_patients/human_referral_prac_000039.jsp∣=WC0b01ac05805c516f.
  19. US Food and Drug Administration (2017). FDA Drug Safety Communication: FDA Restricts Use of Prescription Codeine Pain and Cough Medicines and Tramadol Pain Medicines in Children; Recommends Against use in Breastfeeding Women. In: FDA [internet]. [cit. 9-8-2022]. Available from: https://www.fda.gov/downloads/Drugs/DrugSafety/UCM553814.pdf.
  20. Boulkedid R, Abdou AY, Desselas E, et al. GAPP Consortium. The research gap in chronic paediatric pain: A systematic review of randomised controlled trials. Eur J Pain. 2018;22(2):261-271. doi: 10.1002/ejp.1137. Epub 2017 Nov 5. PMID: 29105908. Go to original source... Go to PubMed...




Pediatrics for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.